HRP20180387T1 - Oralne formulacije deferasiroksa - Google Patents
Oralne formulacije deferasiroksa Download PDFInfo
- Publication number
- HRP20180387T1 HRP20180387T1 HRP20180387TT HRP20180387T HRP20180387T1 HR P20180387 T1 HRP20180387 T1 HR P20180387T1 HR P20180387T T HRP20180387T T HR P20180387TT HR P20180387 T HRP20180387 T HR P20180387T HR P20180387 T1 HRP20180387 T1 HR P20180387T1
- Authority
- HR
- Croatia
- Prior art keywords
- tablet
- deferasirox
- film
- oral administration
- administration according
- Prior art date
Links
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 title claims 9
- 229960001489 deferasirox Drugs 0.000 title claims 9
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003826 tablet Substances 0.000 claims 13
- 239000007941 film coated tablet Substances 0.000 claims 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 4
- 229960000913 crospovidone Drugs 0.000 claims 4
- 235000019359 magnesium stearate Nutrition 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 229920001993 poloxamer 188 Polymers 0.000 claims 3
- 229940044519 poloxamer 188 Drugs 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Claims (9)
1. Filmom obložena tableta za oralnu primjenu, naznačena time, da ona
obuhvaća deferasiroks ili njegovu farmaceutski prihvatljivu sol, koji/koja je prisutan/prisutna u količini od 45 do 60 masenih postotaka na osnovi ukupne mase tablete, te time, da tableta sadrži 90 mg, 180 mg ili 360 mg deferasiroksa ili njegove farmaceutski prihvatljive soli,
pri čemu tableta nadalje obuhvaća sljedeće:
(i) najmanje jedno punilo u ukupnoj količini od 10 do 40 masenih postotaka na osnovi ukupne mase tablete, gdje to punilo je mikrokristalna celuloza;
(ii) najmanje jedan dezintegrator u ukupnoj količini od jednoga do 10 masenih postotaka na osnovi ukupne mase tablete, gdje taj dezintegrator je unakrsno povezani polivinilpirolidon (krospovidon);
(iii) najmanje jedno vezivo u ukupnoj količini od jednoga do 5 masenih postotaka na osnovi ukupne mase tablete, gdje to vezivo je polivinilpirolidon (PVP);
(iv) prema potrebi, najmanje jedan tenzid u ukupnoj količini od 0,0 do dva masena postotka na osnovi ukupne mase tablete, gdje taj tenzid je poloksamer;
(v) najmanje jedno klizno sredstvo u ukupnoj količini od 0,1 do jednog masenog postotka na osnovi ukupne mase tablete, gdje to klizno sredstvo je koloidni silicijev dioksid;
(vi) najmanje jedan lubrikant u ukupnoj količini od manje od 0,1 do dva masena postotka na osnovi ukupne mase tablete, gdje taj lubrikant je magnezijev stearat; i
(vii) obloga.
2. Filmom obložena tableta za oralnu primjenu prema zahtjevu 1, naznačena time, da tableta obuhvaća 90 mg deferasiroksa ili njegove farmaceutski prihvatljive soli.
3. Filmom obložena tableta za oralnu primjenu prema zahtjevu 1, naznačena time, da tableta obuhvaća 180 mg deferasiroksa ili njegove farmaceutski prihvatljive soli.
4. Filmom obložena tableta za oralnu primjenu prema zahtjevu 1, naznačena time, da tableta obuhvaća 360 mg deferasiroksa ili njegove farmaceutski prihvatljive soli.
5. Filmom obložena tableta za oralnu primjenu prema bilo kojem od prethodnih zahtjeva, naznačena time, da tableta pokazuje vrijeme dezintegracije u trajanju od 5-10 minuta kada se mjeri standardnim USP testom dezintegracije.
6. Filmom obložena tableta za oralnu primjenu prema zahtjevu 1, naznačena time, da se ona sastoji od: 90 mg deferasiroksa;
53,61 mg mikrokristalne celuloze;
3,65 mg polivinilpirolidona;
11,34 mg krospovidona;
0,16 mg poloksamera 188;
0,81 mg koloidnog silicijevog dioksida;
2,43 mg magnezijevog stearata; i
4,86 mg obloge.
7. Filmom obložena tableta za oralnu primjenu prema zahtjevu 1, naznačena time, da se ona sastoji od: 180 mg deferasiroksa;
107,23 mg mikrokristalne celuloze;
7,29 mg polivinilpirolidona;
22,68 mg krospovidona;
0,32 mg poloksamera 188;
1,62 mg koloidnog silicijevog dioksida;
4,86 mg magnezijevog stearata; i
9,72 mg obloge.
8. Filmom obložena tableta za oralnu primjenu prema zahtjevu 1, naznačena time, da se ona sastoji od: 360 mg deferasiroksa;
215,45 mg mikrokristalne celuloze;
14,58 mg polivinilpirolidona;
45,36 mg krospovidona;
0,65 mg poloksamera 188;
3,24 mg koloidnog silicijevog dioksida;
9,72 mg magnezijevog stearata; i
19,44 mg obloge.
9. Filmom obložena tableta za oralnu primjenu prema zahtjevu 1, naznačena time, da ona obuhvaća sljedeće:
[image]
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361774893P | 2013-03-08 | 2013-03-08 | |
US201361824435P | 2013-05-17 | 2013-05-17 | |
EP16188627.0A EP3124018B2 (en) | 2013-03-08 | 2014-03-06 | Oral formulations of deferasirox |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20180387T1 true HRP20180387T1 (hr) | 2018-04-20 |
Family
ID=50288212
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180387TT HRP20180387T1 (hr) | 2013-03-08 | 2018-03-06 | Oralne formulacije deferasiroksa |
HRP20190173TT HRP20190173T1 (hr) | 2013-03-08 | 2019-01-25 | Oralne formulacije deferasiroksa |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20190173TT HRP20190173T1 (hr) | 2013-03-08 | 2019-01-25 | Oralne formulacije deferasiroksa |
Country Status (42)
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3570B1 (ar) | 2013-03-08 | 2020-07-05 | Novartis Ag | صيغ للإعطاء بالفم من ديفيرازيروكس |
US9866684B2 (en) * | 2015-02-16 | 2018-01-09 | Microsoft Technology Licensing, Llc | Process for real-time data exchange between users on a phone call |
WO2016167729A1 (en) * | 2015-04-16 | 2016-10-20 | Öğün Yusuf Toktamiş | Dispersible tablets comprising deferasirox |
EP3310354A4 (en) | 2015-06-17 | 2018-12-12 | Dispersol Technologies, LLC | Improved formulations of deferasirox and methods of making the same |
WO2017158559A1 (en) | 2016-03-17 | 2017-09-21 | Lupin Limited | Compositions of deferasirox |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
EP3481390A4 (en) * | 2016-07-05 | 2020-03-04 | Jubilant Generics Limited | PHARMACEUTICAL COMPOSITION WITH IMMEDIATE RELEASE OF IRON CHELATE IMAGERS |
WO2018059922A1 (en) | 2016-09-30 | 2018-04-05 | Synthon B.V. | Pharmaceutical composition comprising deferasirox |
CZ2017255A3 (cs) * | 2017-05-04 | 2018-11-14 | Zentiva, K.S. | Filmem potažené tablety Deferasiroxu |
TR201707764A2 (tr) * | 2017-05-29 | 2018-12-21 | Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi | Deferasiroksun bölünebilir tablet formları. |
WO2019108156A1 (en) * | 2017-11-28 | 2019-06-06 | Biofarma Ilac Sanayi Ve Ticaret A.S. | A scored tablet formulation comprising deferasirox in a film tablet form |
KR20200113116A (ko) | 2019-03-22 | 2020-10-06 | 주식회사 한국팜비오 | 데페라시록스를 포함하는 필름코팅정제 |
EP4052698A1 (en) * | 2021-03-05 | 2022-09-07 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Film coated tablet comprising deferasirox |
CN115154428B (zh) * | 2022-09-06 | 2023-01-10 | 上海奥科达医药科技股份有限公司 | 一种地拉罗司药物组合物及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW533205B (en) | 1996-06-25 | 2003-05-21 | Novartis Ag | Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition |
GB0223978D0 (en) * | 2002-10-15 | 2002-11-20 | Novartis Ag | Organic compound |
GB0408078D0 (en) * | 2004-04-08 | 2004-05-12 | Novartis Ag | Organic compounds |
KR20070022243A (ko) * | 2004-04-08 | 2007-02-26 | 노파르티스 아게 | 데페라시록스 분산성 정제 |
WO2007045445A1 (en) * | 2005-10-19 | 2007-04-26 | Novartis Ag | Dispersible tablets comprising deferasirox |
US20090142395A1 (en) * | 2007-11-19 | 2009-06-04 | Uri Zadok | Deferasirox pharmaceutical compositions |
WO2009106824A2 (en) | 2008-02-25 | 2009-09-03 | Cipla Limited | Pharmaceutical formulations |
US20110097413A1 (en) | 2008-04-21 | 2011-04-28 | Actavis Group Ptc Ehf | Solid state forms of deferasirox salts and process for the preparation thereof |
WO2010035282A1 (en) | 2008-09-24 | 2010-04-01 | Matrix Laboratories Limited | Pharmaceutical compositions comprising deferasirox |
WO2010143006A1 (en) * | 2009-06-10 | 2010-12-16 | Carlo Ghisalberti | Orally bioavailable iron chelators in the treatment of an inflammatory bowel disease |
US8703203B2 (en) * | 2010-07-08 | 2014-04-22 | Ratiopharm Gmbh | Oral dosage form of deferasirox |
RU2589842C2 (ru) * | 2010-10-01 | 2016-07-10 | Сипла Лимитед | Фармацевтическая композиция |
JO3570B1 (ar) | 2013-03-08 | 2020-07-05 | Novartis Ag | صيغ للإعطاء بالفم من ديفيرازيروكس |
WO2017158559A1 (en) | 2016-03-17 | 2017-09-21 | Lupin Limited | Compositions of deferasirox |
-
2014
- 2014-03-06 JO JOP/2014/0075A patent/JO3570B1/ar active
- 2014-03-06 MX MX2015011962A patent/MX361055B/es active IP Right Grant
- 2014-03-06 EA EA201591665A patent/EA031719B1/ru not_active IP Right Cessation
- 2014-03-06 ES ES14710654T patent/ES2708955T5/es active Active
- 2014-03-06 LT LTEP16188627.0T patent/LT3124018T/lt unknown
- 2014-03-06 AP AP2015008668A patent/AP2015008668A0/xx unknown
- 2014-03-06 PL PL16188627T patent/PL3124018T3/pl unknown
- 2014-03-06 SI SI201431064T patent/SI2964202T1/sl unknown
- 2014-03-06 KR KR1020177010591A patent/KR20170045391A/ko not_active Application Discontinuation
- 2014-03-06 TW TW103107731A patent/TWI625136B/zh active
- 2014-03-06 SG SG10201807204YA patent/SG10201807204YA/en unknown
- 2014-03-06 SG SG11201506491RA patent/SG11201506491RA/en unknown
- 2014-03-06 EP EP16188627.0A patent/EP3124018B2/en active Active
- 2014-03-06 US US14/198,872 patent/US9283209B2/en active Active
- 2014-03-06 KR KR1020157027470A patent/KR101925671B1/ko active IP Right Grant
- 2014-03-06 WO PCT/IB2014/059494 patent/WO2014136079A1/en active Application Filing
- 2014-03-06 AU AU2014224198A patent/AU2014224198B2/en active Active
- 2014-03-06 CN CN201480012815.XA patent/CN105025886B/zh active Active
- 2014-03-06 UY UY0001035367A patent/UY35367A/es not_active Application Discontinuation
- 2014-03-06 PE PE2015001870A patent/PE20151600A1/es unknown
- 2014-03-06 PT PT161886270T patent/PT3124018T/pt unknown
- 2014-03-06 SI SI201430621T patent/SI3124018T1/en unknown
- 2014-03-06 CA CA2890465A patent/CA2890465A1/en not_active Abandoned
- 2014-03-06 PL PL14710654T patent/PL2964202T3/pl unknown
- 2014-03-06 RS RS20190142A patent/RS58317B1/sr unknown
- 2014-03-06 DK DK16188627.0T patent/DK3124018T3/en active
- 2014-03-06 TW TW107112193A patent/TWI686215B/zh active
- 2014-03-06 MY MYPI2015702695A patent/MY170303A/en unknown
- 2014-03-06 EP EP14710654.6A patent/EP2964202B2/en active Active
- 2014-03-06 NZ NZ711179A patent/NZ711179A/en unknown
- 2014-03-06 ES ES16188627.0T patent/ES2663135T3/es active Active
- 2014-03-06 LT LTEP14710654.6T patent/LT2964202T/lt unknown
- 2014-03-06 CU CUP2015000110A patent/CU24348B1/xx unknown
- 2014-03-06 RS RS20180167A patent/RS56890B1/sr unknown
- 2014-03-06 DK DK14710654.6T patent/DK2964202T3/en active
- 2014-03-06 ME MEP-2019-30A patent/ME03297B/me unknown
- 2014-03-06 PT PT14710654T patent/PT2964202T/pt unknown
- 2014-03-06 JP JP2015560837A patent/JP6434429B2/ja active Active
- 2014-03-06 HU HUE14710654A patent/HUE041224T2/hu unknown
- 2014-03-06 HU HUE16188627A patent/HUE036921T2/hu unknown
- 2014-03-06 BR BR112015021254A patent/BR112015021254A2/pt not_active IP Right Cessation
-
2015
- 2015-05-12 SA SA515360425A patent/SA515360425B1/ar unknown
- 2015-08-20 ZA ZA2015/06060A patent/ZA201506060B/en unknown
- 2015-08-24 IL IL240797A patent/IL240797B/en unknown
- 2015-09-04 TN TN2015000393A patent/TN2015000393A1/en unknown
- 2015-09-07 NI NI201500126A patent/NI201500126A/es unknown
- 2015-09-07 CL CL2015002495A patent/CL2015002495A1/es unknown
- 2015-09-07 PH PH12015501981A patent/PH12015501981A1/en unknown
- 2015-09-08 CR CR20150467A patent/CR20150467A/es unknown
- 2015-09-08 DO DO2015000220A patent/DOP2015000220A/es unknown
- 2015-10-08 EC ECIEPI201542897A patent/ECSP15042897A/es unknown
-
2016
- 2016-01-13 HK HK16100339.2A patent/HK1212242A1/xx active IP Right Maintenance
- 2016-02-05 US US15/017,084 patent/US20160220493A1/en not_active Abandoned
-
2017
- 2017-06-08 AU AU2017203897A patent/AU2017203897B2/en active Active
- 2017-06-16 US US15/625,863 patent/US20170290811A1/en not_active Abandoned
-
2018
- 2018-03-06 HR HRP20180387TT patent/HRP20180387T1/hr unknown
- 2018-03-12 CY CY20181100302T patent/CY1120021T1/el unknown
- 2018-03-23 US US15/934,595 patent/US20180221285A1/en not_active Abandoned
- 2018-05-24 JP JP2018099612A patent/JP6739470B2/ja active Active
-
2019
- 2019-01-25 HR HRP20190173TT patent/HRP20190173T1/hr unknown
- 2019-01-31 CY CY20191100143T patent/CY1121315T1/el unknown
-
2020
- 2020-06-08 JP JP2020099402A patent/JP2020180123A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20180387T1 (hr) | Oralne formulacije deferasiroksa | |
IL273300B1 (en) | High dose valbenazine formulation and related preparations, methods and kits | |
HRP20192026T1 (hr) | Formulacija tableta od neratinib maleata | |
HRP20160880T4 (hr) | Formulacija obložene tablete i postupak | |
WO2009034541A3 (en) | Controlled release pharmaceutical dosage forms of trimetazidine | |
NZ602075A (en) | Abuse-resistant formulations | |
JP2011098964A5 (hr) | ||
HRP20211862T1 (hr) | Pripravci za i postupci liječenja anemije | |
RS51330B (en) | STABLE PHARMACEUTICAL FORMULATIONS OF MONTELUKAST SODIUM | |
CO6400186A2 (es) | Tabletas de acetato de ulipristal | |
RU2011152105A (ru) | Составы таблеток 3-цианохинолина и их применение | |
NZ604055A (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate | |
MX354416B (es) | Formulaciones a base de nalbufina y sus usos. | |
WO2011147026A3 (en) | A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide | |
WO2016210003A3 (en) | 17-hydroxyprogesterone ester-containing oral compositions and related methods | |
HRP20230616T1 (hr) | Disperzivni pripravci | |
BR112013017750A2 (pt) | nanocápsulas com envoltório polimérico | |
BR112014009438A2 (pt) | composição farmacêutica para administração oral, e, método de preparação da composição farmacêutica para administração oral | |
HRP20192227T1 (hr) | Dvojna uporaba oralnog farmaceutskog pripravka tableta sulfatnih soli i metode njihove uporabe | |
CO6150126A2 (es) | Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina | |
WO2019059953A3 (en) | Dry powder compositions with magnesium stearate | |
BR112015001640A2 (pt) | formulações e métodos de produção de formulações para uso em evacuação colônica | |
CA2797458A1 (en) | Tablet formulation of ezatiostat | |
RU2019109695A (ru) | Лекарственная форма для пролонгированного ослабления симптомов | |
BR112015014430A2 (pt) | composição em comprimido, e, granulado adequado para a fabricação de uma composição em comprimido |